Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,156)

Items 301–400 of 12,156

1. The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action
   Éloi Marijon, Kumar Narayanan, Karen L. Smith, Sérgio Barra, Cristina Basso, Marieke T. Blom, Lia Crotti, André d’Ávila, Rajat Deo, Florence Dumas et al. · 2023 · The Lancet
2. 2023 ESC Guidelines for the management of acute coronary syndromes
   Robert A. Byrne, Xavier Rosselló, John Joseph Coughlan, Emanuele Barbato, Colin Berry, Alaide Chieffo, Marc J. Claeys, Gheorghe‐Andrei Dan, Marc Richard Dweck, Mary Galbraith et al. · 2023 · European Heart Journal Acute Cardiovascular Care
3. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
   Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Cefalu, William T., Januzzi, James L., Kalyani, Rita Rastogi, Kosiborod, Mikhail, Magwire, Melissa L., Morris, Pamela B. et al. · 2018 · Journal of the American College of Cardiology
4. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions
   Sanajou, Davoud, Ghorbani Haghjo, Amir, Argani, Hassan, Aslani, Somayeh · 2018 · European Journal of Pharmacology
5. Heart Failure With Preserved Ejection Fraction and Diabetes
   McHugh, Kelly, DeVore, Adam D., Wu, Jingjing, Matsouaka, Roland A., Fonarow, Gregg C., Heidenreich, Paul A., Yancy, Clyde W., Green, Jennifer B., Altman, Natasha, Hernandez, Adrian F. · 2019 · Journal of the American College of Cardiology
6. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
   Tentolouris, Anastasios, Vlachakis, Panayotis, Tzeravini, Evangelia, Eleftheriadou, Ioanna, Tentolouris, Nikolaos · 2019 · International Journal of Environmental Research and Public Health
7. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives
   M. Evans, R. D. Lewis, A. Morgan, M. Whyte, W. Hanif, Stephen C. Bain, S. Davies, U. Dashora, Z. Yousef, D. Patel et al. · 2021 · Advances in Therapy
8. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management
   Ebenezer A. Nyenwe, Abbas E. Kitabchi · 2015 · Metabolism
9. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
   Naveed A. Sattar, James B. McLaren, Søren Lund Kristensen, David Preiss, John J.V. McMurray · 2016 · Diabetologia
10. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
    Lipska, Kasia J., Krumholz, Harlan, Soones, Tacara, Lee, Sei J. · 2016 · JAMA
11. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
    Fabrice Bonnet, André Jacques Scheen · 2018 · Diabetes & Metabolism
12. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
    Jhund, Pardeep S., Solomon, Scott D., Docherty, Kieran F., Heerspink, Hiddo J.L., Anand, Inder S., Böhm, Michael, Chopra, Vijay, de Boer, Rudolf A., Desai, Akshay S., Ge, Junbo et al. · 2021 · Circulation
13. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013
    Lipska, Kasia J., Yao, Xiaoxi, Herrin, Jeph, McCoy, Rozalina G., Ross, Joseph S., Steinman, Michael A., Inzucchi, Silvio E., Gill, Thomas M., Krumholz, Harlan M., Shah, Nilay D. · 2017 · Diabetes Care
14. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
    Thomas Ray Einarson, Annabel Acs, Craig Ludwig, Ulrik Haagen Panton · 2018 · Value in Health
15. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
    Stefan Karl James, David Erlinge, Robert F. Storey, Darren K. McGuire, Mark de Belder, Niclas Eriksson, Kasper Andersen, David Austin, Gabriel Arefalk, David Carrick et al. · 2023 · NEJM Evidence
16. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
    Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
17. Neuroprotective effect of SGLT2 inhibitors.
    Pawlos, Agnieszka, Broncel, Marlena, Woźniak, Ewelina, Gorzelak-Pabiś, Paulina · 2021 · Molecules
18. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
    Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida et al. · 2023 · Journal of Atherosclerosis and Thrombosis
19. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
    American Diabetes Association · 2017 · Diabetes Care
20. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Yun, Jae-Seung, Ko, Seung-Hyun · 2021 · Metabolism
21. Empagliflozin after Acute Myocardial Infarction
    Javed Butler, W. Schuyler Jones, Jacob Allen Udell, Stefan D. Anker, Mark Colquhoun Petrie, Josephine Harrington, Michaela Mattheus, Isabella Zwiener, Offer Amir, Maria Cecilia Bahit et al. · 2024 · New England Journal of Medicine
22. American Association of Diabetes Educators 2017
    Ann M. Carracher, Payal H. Marathe, Kelly L. Close · 2017 · Journal of Diabetes
23. Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease
    Viviany R. Taqueti, Leslee J. Shaw, Nancy R. Cook, Venkatesh Locharla Murthy, Nishant R. Shah, Courtney R. Foster, Jon Mark Hainer, Ron Blankstein, Sharmila Dorbala, Marcelo F. Di Carli · 2016 · Circulation
24. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score
    Matthew W. Segar, Muthiah Vaduganathan, Kershaw V. Patel, Darren K. McGuire, Javed Butler, Gregg C. Fonarow, Mujeeb A. Basit, Vaishnavi Kannan, Justin Lee Grodin, Brendan M. Everett et al. · 2019 · Diabetes Care
25. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies
    Jessica Myers Franklin, Elisabetta Patorno, Rishi J. Desai, Robert J. Glynn, David Martin, Kenneth Quinto, Ajinkya M Pawar, Lily Gui Bessette, Hemin Lee, Elizabeth M. Garry et al. · 2020 · Circulation
26. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
    Sebastian Steven, Matthias Walter Oelze, Alina Hanf, Swenja Kröller‐Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschof, Maximilian Kopp, Ute Gödtel‐Armbrust, Ning Xia et al. · 2017 · Redox Biology
27. Nocturnal Hypertension: New Technology and Evidence
    Kario, Kazuomi · 2018 · Hypertension
28. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
    Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2019 · Endocrine Practice
29. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
    Aroda, V.R., Ahmann, A., Cariou, B., Chow, F., Davies, M.J., Jódar, E., Mehta, R., Woo, V., Lingvay, I. · 2019 · Diabetes & Metabolism
30. Very-Low-Calorie Ketogenic Diet (VLCKD) in the Management of Metabolic Diseases: Systematic Review and Consensus Statement from the Italian Society of Endocrinology (SIE)
    Caprio, M., Infante, M., Moriconi, E., Armani, A., Fabbri, A., Mantovani, G., Mariani, S., Lubrano, C., Poggiogalle, E., Migliaccio, S. et al. · 2019 · Journal of Endocrinological Investigation
31. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
    Muhammad A Abdul‐Ghani, Stefano Del Prato, ROBERT J. CHILTON, Ralph Anthony DeFronzo · 2016 · Diabetes Care
32. Hypertension and diabetes: co-prediction and time trajectories
    V. Tsimihodimos, C. González-Villalpando, J. Meigs, E. Ferrannini · 2018 · HYPERTENSION
33. 11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2022</i>
    American Diabetes Association Professional Practice Committee · 2022 · Diabetes Care
34. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
    Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George et al. · 2019 · Circulation
35. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
    Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li, Tong Liu · 2019 · Cardiovascular Diabetology
36. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
    Brendon Lange Neuen, Megumi Oshima, Rajiv Agarwal, Clare Gabrielle Arnott, David Z.I. Cherney, Robert Edwards, Anna Maria Langkilde, Kenneth W. Mahaffey, Darren K. McGuire, Bruce Neal et al. · 2022 · Circulation
37. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
    Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana M. Isaacs, Eric L. Johnson et al. · 2022 · Diabetes Care
38. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
    de Boer, Ian H., Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A. et al. · 2020 · Kidney International
39. Cardiovascular Effects of New Oral Glucose-Lowering Agents
    André Jacques Scheen · 2018 · Circulation Research
40. Cardiomyopathy in obesity, insulin resistance and diabetes
    Michinari Nakamura, Junichi Sadoshima · 2019 · The Journal of Physiology
41. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging
    Kidokoro, Kengo, Cherney, David Z.I., Bozovic, Andrea, Nagasu, Hajime, Satoh, Minoru, Kanda, Eiichiro, Sasaki, Tamaki, Kashihara, Naoki · 2019 · Circulation
42. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
    Han, Ji Hye, Oh, Tae Jung, Lee, Ghayoung, Maeng, Hyo Jin, Lee, Dong Hwa, Kim, Kyoung Min, Choi, Sung Hee, Jang, Hak Chul, Lee, Hye Seung, Park, Kyong Soo et al. · 2017 · Diabetologia
43. Leptin, cardiovascular diseases and type 2 diabetes mellitus
    Niki Katsiki, Dimitri P. Mikhailidis, Maciej Banach · 2018 · Acta Pharmacologica Sinica
44. Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
    Giuseppe Defeudis, Rossella Mazzilli, Marta Tenuta, Giovanni Rossini, Virginia Zamponi, Soraya Olana, Antongiulio Faggiano, Paolo Pozzilli, Andrea Maria Isidori, Daniele Gianfrilli · 2021 · Diabetes/Metabolism Research and Reviews
45. Intention to treat and per protocol analysis in clinical trials
    Tripepi, Giovanni, Chesnaye, Nicholas C., Dekker, Friedo W., Zoccali, Carmine, Jager, Kitty J. · 2020 · Nephrology
46. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
    Katherine R. Tuttle, Frank Chip Brosius, Sharon G. Adler, Matthias Kretzler, Ravindra L. Mehta, James Alan Tumlin, Yoshiya Tanaka, Masakazu Haneda, Jiajun Liu, Maria E. Silk et al. · 2017 · Nephrology Dialysis Transplantation
47. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease
    Gornik, Heather L., Aronow, Herbert D., Goodney, Philip P., Arya, Shipra, Brewster, Luke Packard, Byrd, Lori, Chandra, Venita, Drachman, Douglas E., Eaves, Jennifer M., Ehrman, Jonathan K. et al. · 2024 · Journal of the American College of Cardiology
48. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure
    Michael E. Nassif, Mohammed Qintar, Sheryl L. Windsor, Rita A. Jermyn, David M. Shavelle, Fengming Tang, Sumant Lamba, Kunjan A. Bhatt, John E. Brush, Andrew B. Civitello et al. · 2021 · Circulation
49. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
    Faiez M. Zannad, João Pedro Ferreira, Stuart Pocock, Cordula Zeller, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Sibylle Jenny Hauske, Martina Brueckmann, Egon Pfarr et al. · 2020 · Circulation
50. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
    Daisuke Ito, Satoshi Shimizu, Kazuyuki Inoue, Daigo Saito, Morifumi Yanagisawa, Kouichi Inukai, Yuji Akiyama, Yoshihiro Morimoto, Mitsuhiko Noda, Akira Shimada · 2017 · Diabetes Care
51. Macrovascular Complications in Patients with Diabetes and Prediabetes
    Dou Huang, Marwan M. Refaat, Kamel Mohammedi, Amin Jayyousi, Jassim M. S. Al Suwaidi, Charbel Abi Khalil · 2017 · BioMed Research International
52. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
    Robert Puckrin, Marie‐Philippe Saltiel, Pauline Reynier, Laurent Azoulay, Oriana Hoi Yun Yu, Kristian B. Filion · 2018 · Acta Diabetologica
53. Post-transplant diabetes mellitus in patients with solid organ transplants
    Trond Geir Jenssen, Anders Hartmann · 2019 · Nature Reviews Endocrinology
54. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
    Jorge Ignacio Fonseca-Correa, Ricardo Correa‐Rotter · 2021 · Frontiers in Medicine
55. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
    Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh K. Khunti, Ildiko Lingvay et al. · 2023 · Diabetes Care
56. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
    Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun · 2017 · Scientific Reports
57. The next generation of therapeutics for chronic kidney disease
    Matthew Douglas Breyer, Katalin Suszták · 2016 · Nature Reviews Drug Discovery
58. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
    Blau, Jenny E., Tella, Sri Harsha, Taylor, Simeon I., Rother, Kristina I. · 2017 · Diabetes/Metabolism Research and Reviews
59. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
    Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Satoshi Akagi, Yukihiro Saito, Kentaro Ejiri, Naoaki Matsuo, Keishi Ichikawa, Keiichiro Iwasaki, Takanori Naito et al. · 2022 · International Journal of Molecular Sciences
60. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity
    Packer, Milton · 2018 · Circulation
61. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
    André Jacques Scheen · 2020 · Nature Reviews Endocrinology
62. Carbohydrate-based drugs launched during 2000−2021
    Xin Cao, Xiaojing Du, Heng Jiao, Quanlin An, Ruoxue Chen, Pengfei Fang, Jing Wang, Biao Yu · 2022 · Acta Pharmaceutica Sinica B
63. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
    Ludvik, Bernhard, Frías, Juan P, Tinahones, Francisco J, Wainstein, Julio, Jiang, Honghua, Robertson, Kenneth E, García-Pérez, Luis-Emilio, Woodward, D Bradley, Milicevic, Zvonko · 2018 · The Lancet Diabetes &amp; Endocrinology
64. Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice
    Emily Cokorinos, Jake E. Delmore, Allan R. Reyes, Bina Albuquerque, Rasmus Kjøbsted, Nicolas O. Eskesen, Jean-Luc Tran, Aditi Jatkar, Katherine Cialdea, Ryan M. Esquejo et al. · 2017 · Cell Metabolism
65. Gliflozins in the Management of Cardiovascular Disease
    Eugene Braunwald M. D · 2022 · New England Journal of Medicine
66. Diagnostic approaches for diabetic cardiomyopathy
    Ana Lorenzo-Almorós, José Tuñón, Miguel Orejas, Marcelino Cortés, Jesús Egido, Óscar Lorenzo · 2017 · Cardiovascular Diabetology
67. Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy
    Nina Kaludercic, Fabio Di Lisa · 2020 · Frontiers in Cardiovascular Medicine
68. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya et al. · 2025 · Diabetes Care
69. Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
    Rena M. Pollack, Marc Yves Donath, Derek LeRoith, Gil Leibowitz · 2016 · Diabetes Care
70. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
    Javad Habibi, Annayya Rao Aroor, James R. Sowers, Guanghong Jia, Melvin Ray Hayden, Mona Garro, Brady J. Barron, Eric Mayoux, R. Scott Rector, Adam T. Whaley‐Connell et al. · 2017 · Cardiovascular Diabetology
71. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
    Mikhail Kosiborod, Marília Brito Gomes, Antonio Nicolucci, Stuart Pocock, Wolfgang Rathmann, Marina Vladimirovna Shestakova, Hirotaka Watada, Iichiro Shimomura, Hungta Chen, Javier Cid‐Ruzafa et al. · 2018 · Cardiovascular Diabetology
72. A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
    Aroda, Vanita R. · 2018 · Diabetes, Obesity and Metabolism
73. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
    William Timothy Garvey, Luc Van Gaal, Lawrence A. Leiter, Ujjwala Vijapurkar, James F. List, Robert M Cuddihy, Jimmy Ren, Michael J. Davies · 2018 · Metabolism
74. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway
    Chen Cai, Zhongzhou Guo, Xing Chang, Ziying Li, Feng Wu, Jing He, Tiantian Cao, Kangrong Wang, Nengxian Shi, Hao Zhou et al. · 2022 · Redox Biology
75. Highlights in Heart Failure
    Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, Marco Metra · 2019 · ESC Heart Failure
76. Effects of Icosapent Ethyl on Total Ischemic Events
    Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig et al. · 2019 · Journal of the American College of Cardiology
77. Diabetic Cardiomyopathy
    Stefania Paolillo, Fabio Marsico, Maria Prastaro, Francesco Renga, Luca Esposito, Fabiana De Martino, Pierfrancesco Di Napoli, Immacolata Esposito, Antonio Ambrosio, Monica Ianniruberto et al. · 2019 · Heart Failure Clinics
78. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
    Nikole J. Byrne, Nobutoshi Matsumura, Zaid H. Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M. Darwesh, Jody L. Levasseur, James W.S. Jahng, Dyonne Y. Vos, Nirmal Parajuli et al. · 2020 · Circulation Heart Failure
79. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Alexander Yur'evich Mayorov, Ol'ga Konstantinovna Vikulova, Gagik Radikovich Galstyan, Тамара Леонидовна Кураева, Valentina Aleksandrovna Peterkova, Olga Mikhailovna Smirnova, Elena Georgievna Starostina, Elena Viktorovna Surkova et al. · 2019 · Diabetes Mellitus
80. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
    Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Desai, Mehul, Li, Qiang, Deng, Hsiaowei et al. · 2018 · Circulation
81. Understanding and overcoming metformin gastrointestinal intolerance
    Fabrice Bonnet, André Jacques Scheen · 2016 · Diabetes Obesity and Metabolism
82. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
    Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo et al. · 2022 · International Journal of Molecular Sciences
83. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
    Shaman, Ahmed M., Bain, Stephen C., Bakris, George L., Buse, John B., Idorn, Thomas, Mahaffey, Kenneth W., Mann, Johannes F.E., Nauck, Michael A., Rasmussen, Søren, Rossing, Peter et al. · 2022 · Circulation
84. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
    Michael A. Weber, Traci A. Mansfield, Valerie A. Cain, Nayyar Iqbal, Shamik J. Parikh, Agata Ptaszynska · 2015 · The Lancet Diabetes & Endocrinology
85. Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
    Arnott, Clare, Li, Qiang, Kang, Amy, Neuen, Brendon L., Bompoint, Severine, Lam, Carolyn S. P., Rodgers, Anthony, Mahaffey, Kenneth W., Cannon, Christopher P., Perkovic, Vlado et al. · 2020 · Journal of the American Heart Association
86. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials
    Dandan Li, Tiansheng Wang, Su Shen, Zhenwei Fang, Yue Dong, Huilin Tang · 2016 · Diabetes Obesity and Metabolism
87. Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
    Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, Frédéric Jaisser · 2021 · Nature Reviews Nephrology
88. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients
    Latva-Rasku, Aino, Honka, Miikka-Juhani, Kullberg, Joel, Mononen, Nina, Lehtimäki, Terho, Saltevo, Juha, Kirjavainen, Anna K., Saunavaara, Virva, Iozzo, Patricia, Johansson, Lars et al. · 2019 · Diabetes Care
89. Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys
    Motoaki Sano, Makoto Takei, Yasuyuki Shiraishi, Yoshihiko Suzuki · 2016 · Journal of Clinical Medicine Research
90. ESVM Guideline on peripheral arterial disease
    Ulrich Frank, Sigrid Nikol, J. J. F. Belch, Vinko Boc, Marianne Brodmann, P. Carpentier, Ali Chraim, Caitríona Canning, Evangelos P. Dimakakos, Anders Gottsäter et al. · 2019 · VASA
91. Twenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study
    Kario, Kazuomi, Okada, Kenta, Kato, Mitsutoshi, Nishizawa, Masafumi, Yoshida, Tetsuro, Asano, Tsuguyoshi, Uchiyama, Kazuaki, Niijima, Yawara, Katsuya, Tomohiro, Urata, Hidenori et al. · 2019 · Circulation
92. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
    Lee, Dustin M., Battson, Micah L., Jarrell, Dillon K., Hou, Shuofei, Ecton, Kayl E., Weir, Tiffany L., Gentile, Christopher L. · 2018 · Cardiovascular Diabetology
93. Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
    Jin, Qiao, Ma, Ronald Ching Wan · 2021 · Cells
94. Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial
    Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet M. Schnee, Karen A. Kimura, Cordula Zeller, Jyothis Thomas George, Martina Brueckmann et al. · 2019 · European Journal of Heart Failure
95. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
    Spertus, John A., Birmingham, Mary C., Nassif, Michael, Damaraju, C. V., Abbate, Antonio, Butler, Javed, Lanfear, David E., Lingvay, Ildiko, Kosiborod, Mikhail N., Januzzi, James L. · 2022 · Nature Medicine
96. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
    Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Kayoko Ikehara, Eiichiro Kanda, Hiroshi Uchino, Takahisa Hirose · 2017 · Cardiovascular Diabetology
97. Hypertension and Heart Failure
    Jeremy A. Slivnick, Brent C. Lampert · 2019 · Heart Failure Clinics
98. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
    Cherney, David Z.I., Cooper, Mark E., Tikkanen, Ilkka, Pfarr, Egon, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Lund, Søren S. · 2018 · Kidney International
99. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial
    Kosiborod, Mikhail N, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay et al. · 2021 · The Lancet Diabetes &amp; Endocrinology
100. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
     Clifford J. Bailey, Caroline Day, Srikanth Bellary · 2022 · Current Diabetes Reports